Health Condition 1: L910- Hypertrophic scar
Conditions
Interventions
Intervention1: Botulinum Toxin Type A: Preparation: Reconstitution of 100 U vial with 2.5 mL sterile normal saline (40 U/mL concentration)
Dosage: 5 U/cm of scar surface area, maximum 50 U per sessi
Sponsors
Dr Nishita Maheshwari
Dr Kuldeep Singh
Eligibility
Inclusion criteria
Inclusion criteria: Clinical diagnosis of hypertrophic scar (raised, red, firm scar within original wound boundaries) Scar duration more than 3 months and less than 12 months Scar dimensions more than 1 cm in any direction to allow adequate assessment and treatment No previous intralesional therapy for the study scar within 6 months
Exclusion criteria
Exclusion criteria: Keloid scars (extension beyond original wound boundaries with tendency for progressive growth) Scars bigger than 10 cm2 Pregnancy or lactation Known hypersensitivity to botulinum toxin or triamcinolone acetonide Active infection or inflammatory condition at injection site Neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome, ALS) Patients lost to follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient and Observer Scar Assessment Scale (POSAS)Timepoint: 6 months post treatment initiation | — |
Secondary
| Measure | Time frame |
|---|---|
| Vancouver Scar Scale as well as POSASTimepoint: 1 month, 3 months and 6 months post treatment initiation;Quality of life impact using SCAR-Q scaleTimepoint: 1 month, 3 months and 6 months post treatment initiation;Side effect profiles of both interventions, specifically skin atrophy, pigment changes, and telangiectasiaTimepoint: 1 month, 3 months and 6 months post treatment initiation | — |
Countries
India
Contacts
Public ContactDr Nishita Maheshwari
Outcome results
None listed